PL-BIOSCIENCE-GMBH
2.6.2023 07:23:26 CEST | Business Wire | Press release
PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period.
In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption.
About PL BioScience:
Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HPL), offering a complete portfolio of HPL products tailored for various use cases; from standard laboratory research to GMP cell therapies. From academic research, pre-clinical research, and cell therapy, the high quality GMP compliant standards of ELAREM™ ensures seamless transitions of regenerative medicine breakthroughs – from the lab to patients in need.
About Macopharma
Founded in 1977, Macopharma is a major player in the medical devices industry in the blood sector. Based in Tourcoing, in the North of France (59), its development has always been driven by important innovations, results of investments made in research and development and collaborations customers and partners (blood transfusion centers, research laboratories, hospitals...). For all these activities, Macopharma offers a range of solutions that respond to each step of the process from donor to patient.
With more than 2000 employees, 3 plants (in France, Poland and Tunisia) and a presence in nearly 100 countries worldwide, Macopharma's vision is to provide sustainable products and integrated services to ensure safe and secured blood component solutions to every patient in the world.
For more information, visit macopharma.com and follow Linkedin MACOPHARMA
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230601005952/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FuriosaAI Secures $620 Million Series D to Meet Surging Enterprise AI Inference Demand and Accelerate Next-Gen Silicon29.10.2026 00:57:00 CET | Press release
Global investors, including Infinitum, Jericho Capital, QUDA Capital, Cisco Investments, and Worldline Capital, join the round alongside the National Growth Fund of Korea and Korean institutions. FuriosaAI, an AI semiconductor company building sustainable, high-performance inference compute for data centers, today announced the completion of its $620 million (KRW 820 billion) Series D round, bringing its post-money valuation to approximately $2.9 billion. The financing marks a major milestone as FuriosaAI scales global commercial deployments of its RNGD AI inference accelerator. FuriosaAI will use the new capital to expand RNGD production, strengthen its software ecosystem, and accelerate development of its third-generation AI accelerator. International investors contributed a total of $110 million to the round, bringing deep expertise across AI semiconductors and computing infrastructure. U.S.-based Infinitum, an investment firm with extensive experience in the AI semiconductor sector
IFF Declares Dividend for Fourth Quarter 202628.10.2026 21:15:00 CET | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on January 13, 2027 to shareholders of record as of December 19, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20261028159928/en/
Andersen Consulting indgår samarbejde med JKIT28.10.2026 19:57:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital og forretningsmæssig transformation gennem en samarbejdsaftale med John Keells IT (JKIT), en udbyder af teknologiløsninger med base i Sri Lanka. JKIT leverer teknologirådgivning og digitale transformationstjenester til organisationer på tværs af flere brancher, herunder luftfart, finansielle tjenesteydelser, sundhedsvæsen, produktion, detailhandel og telekommunikation. Virksomhedens kompetencer spænder over forretningskritiske applikationer, cloudtransformation, cybersikkerhed, data og analyse, kunstig intelligens samt intelligent automatisering. Gennm strategiske partnerskaber med førende teknologiudbydere som SAP, Microsoft, Salesforce, Databricks og AWS hjælper JKIT organisationer med at modernisere deres teknologiske infrastruktur, effektivisere driften, styrke beslutningsgrundlaget og skabe vækst i forretningen. "Organisationer ønsker i dag at fremskynde deres digitale transformation og ai-tilpasning og har brug for ko
Transition Industries Signs Definitive EPC Agreement with Siemens Energy and Techint E&C for Pacifico Mexinol’s 210 MW Electrolyzer Facility28.10.2026 19:36:00 CET | Press release
Definitive agreement advances delivery of the electrolyzer facility supplying renewable hydrogen for ultra-low-carbon methanol production in Sinaloa, Mexico Transition Industries LLC today announced that it has signed a definitive Engineering, Procurement and Construction (EPC) agreement with Siemens Energy and Techint Engineering & Construction (“Techint E&C”) for the approximately 210 MW electrolyzer facility at its Pacifico Mexinol project in Sinaloa, Mexico. The agreement is subject to customary conditions precedent, including the completion of project financing. The signing builds on the Front-End Engineering Design (FEED) contract announced in August 2025 and represents an important milestone in advancing the project’s renewable hydrogen production infrastructure from engineering toward construction. The facility will incorporate Siemens Energy’s Elyzer P-300 electrolyzer technology and produce renewable hydrogen to support the production of renewable fuels of non-biological orig
Belkin Introduces Infinity Folio for iPad mini, Available Now28.10.2026 19:21:00 CET | Press release
With a precision-engineered hinge that allows flexible viewing angles, all-around drop protection, and a frosted translucent back panel, Infinity Folio is the perfect companion for iPad mini from day one Belkin, a global leader in consumer electronics accessories trusted by more than 1 billion customers worldwide, today introduced Infinity Folio, a beautifully crafted protective case exclusively designed for iPad mini. The Infinity Folio is engineered to protect without compromise. A thin, lightweight and translucent back lets the new iPad mini design shine through with 360° of protection against drops of up to 2 meters*. The ingeniously engineered detachable cover transforms into a stand with multiple viewing angles. Whether it's streaming a favorite show, joining a video call, or reading an exciting book, Infinity Folio adapts to every moment. Designed specifically for iPad mini, Infinity Folio is available at launch through Apple stores and online in select markets worldwide, with a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom